
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a global leader in the pharmaceutical industry with strong international sales and a diverse portfolio of top-selling prescription drugs and vaccines. Although the COVID-19 pandemic has affected its sales in the short term, the company is well-positioned for long-term growth with a strong pipeline and expanding into new areas such as muscle-invasive bladder cancer. The upcoming earnings call will provide insight into the company's progress and future plans, and we maintain a positive outlook on Pfizer's stock.
Bears say
Pfizer is facing challenges with patent expirations, a potential decline in sales from COVID-19 vaccines, and the need for positive pipeline data to improve investor sentiment. The company's 2Q 2026 results showed both positive developments, such as higher than expected Eliquis sales, and negative developments, such as lower COVID sales and reduced guidance. However, with a low 9.3x P/E ratio and a 6.6% dividend yield, the stock is still trading at a discount to its peers.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares